GAPDH and neoplasm: Inhibiting aerobic glycolysis in the tumor microenvironment by targeting GAPDH, a glycolytic pathway shared by both tumor and immune cells, normalizes trophic competition in TIME and reduces the cytotoxic side effects of immunotherapy [43].